|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Celgene
gptkb:MyoKardia
|
|
gptkbp:acquisitionYear
|
2019
2020
|
|
gptkbp:CEO
|
gptkb:Christopher_Boerner
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:division
|
gptkb:R&D
gptkb:Corporate
Manufacturing
Commercial
|
|
gptkbp:focusArea
|
immunology
oncology
cardiovascular diseases
fibrosis
|
|
gptkbp:Fortune500Rank
|
77 (2023)
|
|
gptkbp:founded
|
1887
|
|
gptkbp:founder
|
gptkb:John_Ripley_Myers
gptkb:William_McLaren_Bristol
|
|
gptkbp:headquartersLocation
|
gptkb:New_York_City
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
US1101221083
|
|
gptkbp:logo
|
Bristol-Myers Squibb logo.svg
|
|
gptkbp:marketCap
|
over $100 billion (2023)
|
|
gptkbp:mergedInto
|
1989
|
|
gptkbp:netIncome
|
$6.3 billion (2023)
|
|
gptkbp:notableEmployee
|
gptkb:Christopher_Boerner
gptkb:Giovanni_Caforio
|
|
gptkbp:numberOfEmployees
|
over 34,000
|
|
gptkbp:predecessor
|
gptkb:Squibb_Corporation
gptkb:Bristol-Myers_Company
|
|
gptkbp:products
|
gptkb:Revlimid
gptkb:Eliquis
gptkb:Opdivo
gptkb:Orencia
gptkb:Sprycel
gptkb:Yervoy
|
|
gptkbp:revenue
|
$45.0 billion (2023)
|
|
gptkbp:S&P500Component
|
true
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockSymbol
|
gptkb:BMY
gptkb:NYSE
|
|
gptkbp:subsidiary
|
gptkb:Celgene
gptkb:Juno_Therapeutics
gptkb:MyoKardia
|
|
gptkbp:tradedOn
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.bms.com
|
|
gptkbp:bfsParent
|
gptkb:Laurie_H._Glimcher
gptkb:Louis_V._Gerstner_Jr.
gptkb:Bristol-Myers
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bristol-Myers Squibb
|